Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia · Delayed Price · Currency is MYR 1.380
+0.010 (0.73%)
At close: Sep 12, 2025
Duopharma Biotech Berhad Cash Flow Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 76.52 | 62.65 | 52.65 | 70.11 | 65.68 | 58.61 | Upgrade |
Depreciation & Amortization | 40.56 | 40.58 | 38.76 | 33.48 | 29.66 | 27.56 | Upgrade |
Other Amortization | 4.81 | 4.81 | 4.29 | 2.72 | 2.29 | 1.51 | Upgrade |
Loss (Gain) From Sale of Assets | -0.38 | -0.39 | - | - | 0.01 | - | Upgrade |
Asset Writedown & Restructuring Costs | 0.02 | 0.02 | 2.43 | - | 0.1 | 1.1 | Upgrade |
Provision & Write-off of Bad Debts | -0 | -1.43 | 4.1 | -0.49 | 0.1 | -0.82 | Upgrade |
Other Operating Activities | 20.57 | 11.44 | -7.11 | 22.74 | 7.29 | 12.69 | Upgrade |
Change in Accounts Receivable | -11.38 | -46.6 | -5.81 | -13.28 | -4.14 | 4.54 | Upgrade |
Change in Inventory | -43.05 | -15.35 | -12.39 | -53.36 | -78.43 | -21.37 | Upgrade |
Change in Accounts Payable | 45.69 | 27.62 | -28.1 | 8.35 | 20.64 | -12.48 | Upgrade |
Operating Cash Flow | 133.35 | 83.34 | 48.8 | 70.27 | 43.2 | 71.35 | Upgrade |
Operating Cash Flow Growth | 153.83% | 70.77% | -30.54% | 62.63% | -39.45% | 6.56% | Upgrade |
Capital Expenditures | -34.06 | -23.57 | -32.95 | -65.18 | -109.36 | -56.11 | Upgrade |
Sale of Property, Plant & Equipment | 0.51 | 0.5 | - | - | 0.02 | - | Upgrade |
Sale (Purchase) of Intangibles | -9.66 | -10.32 | -6.61 | -5.84 | -5.64 | -9.51 | Upgrade |
Investment in Securities | - | - | -6.42 | - | -2.07 | 2.68 | Upgrade |
Other Investing Activities | 5.7 | 5.97 | 2.75 | 1.52 | 1.2 | 1.51 | Upgrade |
Investing Cash Flow | -37.51 | -27.43 | -43.23 | -69.5 | -115.86 | -61.43 | Upgrade |
Long-Term Debt Issued | - | 93.37 | 486.35 | 85.67 | 186.78 | 193.81 | Upgrade |
Long-Term Debt Repaid | - | -128.87 | -369.97 | -59.27 | -89.46 | -158.74 | Upgrade |
Net Debt Issued (Repaid) | -32.98 | -35.5 | 116.37 | 26.4 | 97.33 | 35.07 | Upgrade |
Common Dividends Paid | -28.86 | -26.93 | -8.85 | -8.2 | -44.96 | -7.23 | Upgrade |
Financing Cash Flow | -61.84 | -62.43 | 107.52 | 18.2 | 52.37 | 27.83 | Upgrade |
Foreign Exchange Rate Adjustments | 0.34 | 0.56 | -0.23 | 0.69 | 0.24 | -0.4 | Upgrade |
Net Cash Flow | 34.34 | -5.96 | 112.87 | 19.66 | -20.05 | 37.36 | Upgrade |
Free Cash Flow | 99.29 | 59.77 | 15.86 | 5.08 | -66.16 | 15.24 | Upgrade |
Free Cash Flow Growth | 276.33% | 276.91% | 211.98% | - | - | 12.09% | Upgrade |
Free Cash Flow Margin | 11.20% | 7.35% | 2.25% | 0.73% | -10.35% | 2.67% | Upgrade |
Free Cash Flow Per Share | 0.10 | 0.06 | 0.02 | 0.01 | -0.07 | 0.02 | Upgrade |
Cash Interest Paid | 25.8 | 27.02 | 21.71 | 16.54 | 11.97 | 6.34 | Upgrade |
Cash Income Tax Paid | 9.08 | 10.66 | 16.83 | 24.51 | 11.66 | 18.12 | Upgrade |
Levered Free Cash Flow | 69.26 | 31.95 | -10.33 | -6.71 | -60.93 | -7.67 | Upgrade |
Unlevered Free Cash Flow | 84.61 | 48.05 | 0.72 | -1.02 | -56.91 | -3.59 | Upgrade |
Change in Working Capital | -8.75 | -34.32 | -46.3 | -58.29 | -61.93 | -29.3 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.